2 year extension study on Upadacitinib in active AS ⭐️ASAS40 response maintained ⭐️MRI SPARCC scores decreased and maintained ⭐️infections most common AE ⭐️NO MACE, lymphoma, skin cancer, GI perforations Abs#924 #ACR21 #ACRBest @RheumNow https://t.co/725IRAOgtW https://t.co/FVUoCi6aoQ

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

#ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs ⭐️More pts stay on UPA vs ADA (47 vs 36%) ⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq

• https://bit.ly/3GVdSFD

And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy

For rheumatologists, instinct says in RA everything’s better with MTX. For tofacitinib, where immunogenicity not an issue, is that actually true? Canadian registry data: maybe no after 36m, low no. ?valid, markups mine Need to see more of this! #ACR21 ABST0827 ⁦@RheumNow⁩ https://t.co/VVwd4SZgVx

3 year results of SELECT-COMPARE study of upadacitinib. No evidence of a signal in cardiovascular events or cancer. Reassuring, but really need an ORAL-Surveillance style study of upadacitinib to be confident. Abstr#0828 #ACR21 @RheumNow

So it's day 2 at #ACR21, and you know what that means - it's ORAL Surveillance day! This is the figure everyone will be talking about, leading up to details in the plenary. Why are the other bars higher than the pink bars? ABST0831 plenty of @RheumNow coverage coming on this https://t.co/B80cSmhNV7

ORAL Surveillance In mod-severe RA pts >50yo, with CV RF & no hx malignancy, patient-years of exposure required for one event (vs TNFi): MACE tofa 5mg bid: 567 tofa 10mg bid: 319 malignancy tofa 5mg bid: 276 tofa 10mg bid: 275 #ACR21 ABST0831 @RheumNow https://t.co/9vyXPTMFzj

• Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Yea…

Great start to #ACR21 and great recap of the year in rheumatology. Positive data on tofacitinib and AS but still pending approval. Where would JAKinibs be in your AS treatment algorithm?🤔 @RheumNow https://t.co/cs8U33355A